Physician profile
Rex V Lear
NPI 1962445999
$11,306.51
in general payments reported to CMS, 2019-2025
26 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,538 · 2020: $1,014 · 2021: $1,340 · 2022: $1,599 · 2023: $1,490 · 2024: $1,510 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,711 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,711.04 |
| Education | $104.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,777.59 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,729.11 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,089.84 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $855.43 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $733.38 | 2019-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $612.17 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $596.53 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Ironshore Pharmaceuticals INC. | $490.03 | 2019-2023 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $475.25 | 2020-2025 | Caplyta |
| Abbvie INC. | $453.16 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $394.44 | 2019-2022 | |
| Allergan, INC. | $391.99 | 2019-2020 | |
| Indivior INC. | $273.77 | 2022-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $262.70 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $260.43 | 2024-2025 | Cobenfy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $201.68 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $162.40 | 2021-2025 | Qelbree, Qelbree |
| Shire North American Group INC | $114.90 | 2019 | |
| Idorsia Pharmaceuticals US INC | $114.74 | 2022-2023 | Quviviq |
| Corium, LLC | $83.84 | 2022-2023 | Azstarys |
| Merck Sharp & Dohme LLC | $80.06 | 2019-2023 | Belsomra |
| Axsome Therapeutics, INC. | $68.31 | 2023-2025 | Auvelity |
| Biogen, INC. | $44.83 | 2024 | |
| Avanir Pharmaceuticals, INC. | $15.05 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.88 | 2025 | Jornay Pm |
| Tris Pharma INC | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Lear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.